logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Atsushi Hiraoka

ehime prefectural central hospital
H指数:49
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage

阿特珠单抗联合贝伐珠单抗治疗巴塞罗那临床肝细胞癌B2期患者的疗效

Journal of Gastroenterology and Hepatology
IF3.4
2026-09-290
OAAI
Keishi Ouchi; Masashi Ninomiya; Mio Tsuruoka; Jun Inoue; Atsushi Hiraoka; Kosuke Sato; Kotaro Doi; Kengo Watanabe; Tomoya Sasazaki; Takayoshi Oikawa; Kei Endo; Tamami Abe; Masashi Fujita; Kazumichi Abe; Tomohiro Katsumi; Wataru Sato; Chikara Iino; Nobukazu Tanabe; Hiroshi Numao; Hiromasa Ohira; Hidekatsu Kuroda; Yoshiyuki Ueno; Atsushi Masamune
Predictors of long-term changes in mALBI grade in cirrhotic patients after sustained virological response with direct-acting antiviral treatment

直接抗病毒治疗后肝硬化患者mALBI分级长期变化的预测因素

Scientific Reports
IF3.9
2026-08-250
OAAI
Takao Watanabe; Yoshio Tokumoto; Hironori Ochi; Fujimasa Tada; Atsushi Hiraoka; Yoshiyasu Kisaka; Yoshinori Tanaka; Sen Yagi; Seiji Nakanishi; Makoto Morita; Kazuhiko Yamauchi; Makoto Higashino; Kana Hirooka; Atsushi Yukimoto; Yuki Okazaki; Teruki Miyake; Osamu Yoshida; Masashi Hirooka; Masanori Abe; Yoichi Hiasa
Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions

全球不同地理区域真实世界随访中预测SVR后HCC风险模型的验证

Liver International
IF5.2
2026-06-080
OA
Hidenori Toyoda; Yujin Hoshida; Neehar D. Parikh; Prasun K. Jalal; Federico Piñero; Manuel Mendizabal; Ezequiel Ridruejo; Hugo Cheinquer; Andrea Casadei-Gardini; Mounika Kanneganti; Arndt Weinmann; Markus Peck-Radosavljevic; Jean-Francois Dufour; Pompilia Radu; Gamal Shiha; Riham Soliman; Shiv K. Sarin; Manoj Kumar; Jing-Houng Wang; Pisit Tangkijvanich; Wattana Sukeepaisarnjaroen; Masanori Atsukawa; Haruki Uojima; Akito Nozaki; Makoto Nakamuta; Koichi Takaguchi; Atsushi Hiraoka; Hiroshi Abe; Kentaro Matsuura; Tsunamasa Watanabe; Noritomo Shimada; Kunihiko Tsuji; Toru Ishikawa; Shigeru Mikami; Ei Itobayashi; Philip J. Johnson; Amit G. Singal
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma

在初始使用阿替利珠单抗/贝伐珠单抗控制疾病后，疾病进展时基于消融的挽救策略在肝细胞癌中的应用

Hepatology Research
IF3.4
2026-05-110
PRE
Kazuya Kariyama; Kazuhiro Nouso; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Hidenori Toyoda; Satoshi Yasuda; Toshifumi Tada; Kazunari Tanaka; Kunihiko Tsuji; Ei Itobayashi; Akemi Tsutsui; Koichi Takaguchi; Michitaka Imai; Toru Ishikawa; Takeshi Hatanaka; Yuki Kanayama; Satoru Kakizaki; Atsushi Naganuma; Yoshihide Ueda; Tomomitsu Matono; Hideyuki Tamai; Junpei Okamura; Hironori Tanaka; Yutaka Yata; Akiko Wakuta; Masatoshi Kudo; Takashi Kumada
Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models

与恩替卡韦相比，替诺福韦艾拉酚胺在降低乙型肝炎表面抗原方面的卓越疗效：一项使用线性混合效应模型的多中心倾向性评分匹配研究

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
IF6.7
2026-05-040
PRE
Takashi Kumada; Masanori Atsukawa; Norio Itokawa; Taeang Arai; Hidenori Toyoda; Akihito Tsubota; Tsunamasa Watanabe; Makoto Chuma; Kentaro Matsuura; Atsushi Hiraoka; Toshifumi Tada; Koichi Takaguchi; Keizo Kato; Hiroshi Abe; Joji Tani; Toru Ishikawa; Chikara Ogawa; Toru Asano; Tsunekazu Oikawa; Yoshihiro Matsumoto; Tomoyuki Akita; Junko Tanaka
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

不可切除性肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后出血事件的临床特征、预测因素及抗血栓治疗的影响

Hepatology Research
IF3.4
2026-04-210
PRE
Fujimasa Tada; Atsushi Hiraoka; Hideko Ohama; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Yoshihide Ueda; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Jumpei Okamura; Hideyuki Tamai; Shinichiro Nakamura; Yoshiko Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Kazunari Tanaka; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Shohei Komatsu; Takumi Fukumoto; Takanori Matsuura; Soo Ki Kim; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada; the Real-life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

肝内肿瘤负荷对接受阿替利珠单抗联合贝伐珠单抗治疗的合并肝外转移的肝细胞癌患者预后的影响

Hepatology Research
IF3.4
2026-04-100
PRE
Kazunari Tanaka; Kunihiko Tsuji; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Yoshihide Ueda; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Jumpei Okamura; Hideyuki Tamai; Shinichiro Nakamura; Yoshiko Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Fujimasa Tada; Hideko Ohama; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Shohei Komatsu; Takumi Fukumoto; Takanori Matsuura; Soo Ki Kim; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada; the Real-Life Practice Experts for HCC (RELPEC) Study Group and Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

淋巴细胞-单核细胞比值预测接受度鲁单单抗联合曲美单抗治疗的HCC患者的生存情况

Liver International
IF5.2
2026-02-260
PRE
Tomomitsu Matono; Toshifumi Tada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Takashi Nishimura; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Hideyuki Tamai; Shohei Komatsu; Takanori Matsuura; Yoshihide Ueda; Soo Ki Kim; Hideko Ohama; Fujimasa Tada; Shinichiro Nakamura; Yoshiko Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Shinya Fukunishi; Kazunari Tanaka; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Jumpei Okamura; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada; the RELPEC Group and HCC 48 Group
Guidance for Liver Rehabilitation in Chronic Liver Disease

慢性肝病肝脏康复指导

Hepatology Research
IF3.4
2026-01-310
OAAI
Shuji Terai; Hiroteru Kamimura; Yoichi Hiasa; Norio Akuta; Toru Ishikawa; Yuichiro Eguchi; Hironao Okubo; Takumi Kawaguchi; Miwa Kawanaka; Tatsuo Kanda; Masaaki Korenaga; Ryotaro Sakamori; Masahito Shimizu; Yoshio Sumida; Ryosuke Tateishi; Atsushi Tanaka; Naoki Tanaka; Yasuo Tanaka; Yuki Tahata; Masato Nakai; Tadashi Namisaki; Takashi Nishimura; Atsushi Hiraoka; Takeshi Matsui; Nami Mori; Akio Moriya; Tetsuo Takehara
Factors associated with ulcerative colitis with non-anemic iron deficiency

与溃疡性结肠炎伴非贫血性铁缺乏相关的因素

BMC Gastroenterology
IF2.6
2025-11-180
OAAI
Shogo Kitahata; Mai Fukumoto; Kana Matsuoka; Takuya Matsuda; Taisei Murakami; Kei Onishi; Hirofumi Izumoto; Kozue Kanemitsu; Tomoe Kawamura; Taira Kuroda; Junko Matsuoka; Fujimasa Tada; Hideki Miyata; Atsushi Hiraoka; Kazuhiro Tange; Yasunori Yamamoto; Eiji Takeshita; Yoshiou Ikeda; Shinya Furukawa; Eiji Tsubouchi; Tomoyuki Ninomiya; Yoichi Hiasa
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿替利珠单抗联合贝伐珠单抗用于不适合TACE治疗的超出Up-To-7标准的中间阶段肝癌：REPLACEMENT研究的最终分析

Liver International
IF5.2
2025-11-030
OAAI
Kazuomi Ueshima; Kaoru Tsuchiya; Tatsuya Yamashita; Shigeo Shimose; Kazushi Numata; Yuzo Kodama; Shinji Itoh; Yasuhito Tanaka; Hidekatsu Kuroda; Kazuyoshi Ohkawa; Teiji Kuzuya; Masafumi Ikeda; Youhei Kooka; Hiroshi Aikata; Atsushi Hiraoka; Michihisa Moriguchi; Ryosuke Tateishi; Sadahisa Ogasawara; Kouji Yamamoto; Masatoshi Kudo
A New Model to Predict Survival Time in Patients With Hepatocellular Carcinoma With BCLC Advanced Stage

一种预测BCLC晚期肝细胞癌患者生存时间的新模型

Cancer Medicine
IF3.1
2025-10-150
OAAI
Masashi Ninomiya; Mio Tsuruoka; Jun Inoue; Atsushi Hiraoka; Akitoshi Sano; Kosuke Sato; Masazumi Onuki; Satoko Sawahashi; Keishi Ouchi; Kengo Watanabe; Hidekatsu Kuroda; Takayoshi Oikawa; Tamami Abe; Masashi Fujita; Kazumichi Abe; Tomohiro Katsumi; Wataru Sato; Go Igarashi; Chikara Iino; Nobukazu Tanabe; Hiroshi Numao; Hiromasa Ohira; Yoshiyuki Ueno; Atsushi Masamune
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis

度鲁特玛联合特瑞普利单抗在合并门静脉血栓和高肿瘤负荷的肝细胞癌患者中的有效性与安全性：一项多中心回顾性分析

Hepatology Research
IF3.4
2025-09-060
PRE
Hatanaka, Takeshi; Yata, Yutaka; Hiraoka, Atsushi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Kakizaki, Satoru; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Toyoda, Hidenori; Koshiyama, Yuichi; Ogawa, Chikara; Nishikawa, Hiroki; Nishimura, Takashi; Kawata, Kazuhito; Kosaka, Hisashi; Matsui, Kosuke; Naganuma, Atsushi; Tanaka, Hironori; Ohama, Hideko; Kuroda, Hidekatsu; Matono, Tomomitsu; Aoki, Tomoko; Ochi, Hironori; Imai, Michitaka; Nakamura, Shinichiro; Komatsu, Shohei; Tamai, Hideyuki; Okamura, Jumpei; Kanayama, Yuki; Tanaka, Kazunari; Tada, Fujimasa; Yoshida, Osamu; Nouso, Kazuhiro; Morishita, Asahiro; Tsutsui, Akemi; Nagano, Takuya; Itokawa, Norio; Okubo, Tomomi; Arai, Taeang; Matsuura, Takanori; Noritake, Hidenao; Enomoto, Hirayuki; Kaibori, Masaki; Fukumoto, Takumi; Hiasa, Yoichi; Kudo, Masatoshi; Kumada, Takashi
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis

纳武利尤单抗联合伊匹木单抗对比仑伐替尼或索拉非尼作为不可切除肝细胞癌的一线治疗：CheckMate 9DW日本亚组分析

LIVER CANCER
IF9.1
2025-09-016
OA
Kudo, Masatoshi; Hiraoka, Atsushi; Numata, Kazushi; Yamashita, Tatsuya; Kurosaki, Masayuki; Namisaki, Tadashi; Hige, Shuhei; Itoh, Yoshito; Mochida, Satoshi; Hosaka, Tetsuya; Akuta, Norio; Kawaoka, Tomokazu; Genda, Takuya; Kobayashi, Satoshi; Uchida-Kobayashi, Sawako; Lu, Yuting; Ogata, Tatsuya; Jimenez Exposito, Maria Jesus; Ikeda, Masafumi
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma

碳离子放射治疗对于肝细胞癌的治疗效果与手术切除相当。

Hepatology Communications
IF4.6
2025-08-290
OAAI
Hatanaka, Takeshi; Shibuya, Kei; Kakizaki, Satoru; Hiraoka, Atsushi; Tada, Toshifumi; Kariyama, Kazuya; Itobayashi, Ei; Tsuji, Kunihiko; Ishikawa, Toru; Toyoda, Hidenori; Koshiyama, Yuichi; Naganuma, Atsushi; Miyasaka, Yuhei; Kanayama, Yuki; Tanaka, Kazunari; Tada, Fujimasa; Ohama, Hideko; Nouso, Kazuhiro; Nakamura, Shinichiro; Kumada, Takashi; Ohno, Tatsuya; On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma

格瑞特营养风险指数作为不可切除肝癌患者接受度伐利尤单抗联合特瑞普利单抗治疗期间免疫介导不良反应的风险因素的潜在作用

Journal of Gastroenterology
IF5.5
2025-08-200
PRE
Hideko Ohama; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Hideyuki Tamai; Shohei Komatsu; Fujimasa Tada; Shinichiro Nakamura; Yoshiko Nakamura; Teruki Miyake; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Kazunari Tanaka; Takanori Matsuura; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

达鲁瓦鲁单抗联合特雷美鲁单抗在不可切除肝细胞癌老年患者中的安全性与有效性：一项多中心分析

Hepatology Research
IF3.4
2025-08-060
PRE
Tomomitsu Matono; Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Hiroki Nishikawa; Kazunari Tanaka; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Yuichi Koshiyama; Hidenori Toyoda; Chikara Ogawa; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Hidenao Noritake; Hideko Ohama; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Takashi Nishimura; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Tomoko Aoki; Hidekatsu Kuroda; Yutaka Yata; Hideyuki Tamai; Takanori Matsuura; Shohei Komatsu; Yoshihide Ueda; Yoshiko Nakamura; Osamu Yoshida; Kosuke Matsui; Shinichiro Nakamura; Hirayuki Enomoto; Masaki Kaibori; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; the Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group

研究方向

暂未获取到该数据
H
Hidenori Toyoda
H 指数:75论文数:783被引数:2.6万
T
Takashi Kumada
H 指数:70论文数:719被引数:2.1万
T
Toshifumi Tada
H 指数:54论文数:455被引数:1.3万
Y
Yoichi Hiasa
H 指数:59论文数:805被引数:1.7万
M
Masashi Hirooka
H 指数:47论文数:470被引数:8,293
T
Toru Ishikawa
H 指数:46论文数:522被引数:7,884
K
Koichi Takaguchi
H 指数:43论文数:254被引数:6,829
M
Masanori Atsukawa
H 指数:39论文数:354被引数:5,541
E
Ei Itobayashi
H 指数:35论文数:210被引数:3,684
K
Kazuya Kariyama
H 指数:37论文数:210被引数:4,729